Squarepoint’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.61M | Sell |
36,053
-110,355
| -75% | -$20.3M | 0.01% | 1310 |
|
|
2025
Q4 | $25.8M | Buy |
146,408
+138,780
| +1,819% | +$22.7M | 0.03% | 627 |
|
|
2025
Q3 | $1.07M | Sell |
7,628
-29,533
| -79% | -$3.99M | ﹤0.01% | 2635 |
|
|
2025
Q2 | $4.67M | Sell |
37,161
-378,349
| -91% | -$47.1M | ﹤0.01% | 1510 |
|
|
2025
Q1 | $56.9M | Buy |
415,510
+44,309
| +12% | +$6.33M | 0.07% | 305 |
|
|
2024
Q4 | $56.8M | Buy |
371,201
+140,553
| +61% | +$23.7M | 0.06% | 338 |
|
|
2024
Q3 | $44.7M | Buy |
230,648
+226,703
| +5,747% | +$47.4M | 0.07% | 270 |
|
|
2024
Q2 | $915K | Sell |
3,945
-310,764
| -99% | -$67.5M | ﹤0.01% | 2620 |
|
|
2024
Q1 | $67.9M | Buy |
314,709
+224,407
| +249% | +$52.6M | 0.12% | 169 |
|
|
2023
Q4 | $23.4M | Buy |
90,302
+57,514
| +175% | +$14.1M | 0.04% | 501 |
|
|
2023
Q3 | $8.43M | Buy |
32,788
+27,241
| +491% | +$7.29M | 0.02% | 873 |
|
|
2023
Q2 | $1.58M | Buy |
+5,547
| New | +$1.65M | ﹤0.01% | 1828 |
|
|
2023
Q1 | – | Sell |
-138,293
| Closed | -$38.3M | – | 3238 |
|
|
2022
Q4 | $38.3M | Sell |
138,293
-25,482
| -16% | -$7.2M | 0.15% | 126 |
|
|
2022
Q3 | $43.7M | Buy |
163,775
+78,478
| +92% | +$16.7M | 0.22% | 81 |
|
|
2022
Q2 | $17.4M | Sell |
85,297
-171,346
| -67% | -$35M | 0.1% | 229 |
|
|
2022
Q1 | $54M | Buy |
256,643
+252,471
| +6,052% | +$54.9M | 0.23% | 82 |
|
|
2021
Q4 | $1M | Sell |
4,172
-20,904
| -83% | -$5.37M | ﹤0.01% | 1693 |
|
|
2021
Q3 | $7.1M | Buy |
25,076
+3,383
| +16% | +$1.11M | 0.02% | 627 |
|
|
2021
Q2 | $7.51M | Buy |
+21,693
| New | +$6.57M | 0.03% | 561 |
|
|
2021
Q1 | – | Sell |
-4,047
| Closed | -$1.09M | – | 3128 |
|
|
2020
Q4 | $991K | Buy |
+4,047
| New | +$1.04M | 0.01% | 1339 |
|
|
2020
Q3 | – | Sell |
-137,625
| Closed | -$36.8M | – | 2493 |
|
|
2020
Q2 | $36.8M | Buy |
137,625
+136,225
| +9,730% | +$40.9M | 0.6% | 9 |
|
|
2020
Q1 | $443K | Buy |
+1,400
| New | +$425K | 0.01% | 1104 |
|
|
2019
Q4 | – | Sell |
-47,194
| Closed | -$11M | – | 2485 |
|
|
2019
Q3 | $11M | Buy |
47,194
+6,826
| +17% | +$1.59M | 0.1% | 257 |
|
|
2019
Q2 | $9.44M | Sell |
40,368
-19,774
| -33% | -$4.57M | 0.09% | 270 |
|
|
2019
Q1 | $14.2M | Buy |
60,142
+45,477
| +310% | +$14.3M | 0.15% | 153 |
|
|
2018
Q4 | $4.41M | Sell |
14,665
-3,693
| -20% | -$1.18M | 0.05% | 439 |
|
|
2018
Q3 | $6.49M | Sell |
18,358
-9,510
| -34% | -$3.27M | 0.08% | 329 |
|
|
2018
Q2 | $8.09M | Buy |
27,868
+8,822
| +46% | +$2.48M | 0.11% | 289 |
|
|
2018
Q1 | $5.21M | Buy |
19,046
+15,414
| +424% | +$4.78M | 0.08% | 300 |
|
|
2017
Q4 | $1.16M | Sell |
3,632
-4,369
| -55% | -$1.4M | 0.02% | 768 |
|
|
2017
Q3 | $2.5M | Buy |
+8,001
| New | +$2.37M | 0.05% | 445 |
|
|
2017
Q2 | – | Sell |
-4,258
| Closed | -$1.16M | – | 1541 |
|
|
2017
Q1 | $1.16M | Sell |
4,258
-21,953
| -84% | -$6.21M | 0.03% | 553 |
|
|
2016
Q4 | $7.43M | Buy |
+26,211
| New | +$7.77M | 0.3% | 66 |
|
|
2016
Q2 | – | Sell |
-7,461
| Closed | -$1.94M | – | 1105 |
|
|
2016
Q1 | $1.94M | Buy |
+7,461
| New | +$1.97M | 0.15% | 184 |
|
|
2015
Q2 | – | Sell |
-2,842
| Closed | -$1.2M | – | 465 |
|
|
2015
Q1 | $1.2M | Buy |
+2,842
| New | +$1.12M | 0.42% | 68 |
|
Other funds holding BIIB
VCM
VPM
Squarepoint's BIIB Position: Q1 2026 in Review
Squarepoint reduced its Biogen (BIIB) stake by 75% in Q1 2026, selling an estimated $20.3M and leaving 36,053 shares worth $6.61M. The position accounts for 0.01% of the portfolio, ranked #1310.
Squarepoint first reported a position in BIIB in Q1 2015 and has held it in 35 quarters since. The position peaked at $67.9M in Q1 2024. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Squarepoint held 36,053 shares of Biogen worth $6.61M as of Q1 2026.
- Squarepoint sold 110,355 Biogen shares in Q1 2026, an estimated $20.3M.
- Biogen made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1310 holding.
- Squarepoint first reported a position in Biogen in Q1 2015 and has held it in 35 quarters since.
- Squarepoint's Biogen position peaked at $67.9M in Q1 2024.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.